Sonolisib is primarily used in the field of oncology as a targeted therapy for cancer treatment. It functions as a PI3K inhibitor, specifically targeting the PI3K/mTOR pathway, which is often dysregulated in various cancers. By inhibiting this pathway, it helps to reduce tumor growth and proliferation. It is being investigated for its potential in treating solid tumors and hematologic malignancies, particularly in cases where traditional therapies have shown limited efficacy. Additionally, its role in clinical trials focuses on evaluating its safety, tolerability, and effectiveness in combination with other anticancer agents.